home · filing · 0001600620-24-000106
8-K filed November 7, 2024, 6:59 PM ET
ticker AUPH
CIK 0001600620
other material
confidence high
sentiment positive
materiality 0.85
Aurinia Pharmaceuticals Inc. (AUPH): restructuring charge — Aurinia Q3 net product rev $55.5M (+36% YoY), net income $14.4M; restructuring cuts 45% workforce
Aurinia Pharmaceuticals Inc.
Q3 total net revenue $67.8M; net product revenue $55.5M (+36% YoY); net income $14.4M vs loss of $13.4M a year ago.
Strategic restructuring: workforce reduction ~45%, expects annual cash savings >$40M, one-time Q4 charge $15-19M.
FY2024 net product revenue guidance reiterated $210-220M; YTD net product revenue $158.6M.
AUR200 Phase 1 first participant dosed; initial results expected H1 2025.
Board: Craig Johnson appointed, Dr. Robert Foster retired (not due to disagreement).
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-11-07
Filed November 7, 2024, 6:59 PM ET
Effective November 7, 2024, Aurinia issued a press release announcing the appointment of Craig Johnson to the Board of Directors of the Company
Filed November 7, 2024, 6:59 PM ET
Aurinia plans to terminate its employment relationship with Scott Habig.
Effective 2024-11-05
Filed November 7, 2024, 6:59 PM ET
the Company also announced that Dr. Robert T. Foster has retired from the Board effective November 5, 2024.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Craig Johnson was appointed as Director at Aurinia Pharmaceuticals Inc..
Action appointed
Role Director
Exact text from the filing
Effective November 7, 2024, Aurinia issued a press release announcing the appointment of Craig Johnson to the Board of Directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Scott Habig was terminated as Chief Commercial Officer at Aurinia Pharmaceuticals Inc..
Action terminated
Role Chief Commercial Officer
Exact text from the filing
Aurinia plans to terminate its employment relationship with Scott Habig.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Robert T. Foster retired as Director at Aurinia Pharmaceuticals Inc..
Action retired
Role Director
Exact text from the filing
the Company also announced that Dr. Robert T. Foster has retired from the Board effective November 5, 2024.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Aurinia Pharmaceuticals Inc. announced a restructuring with charges of $15 to $19 million affecting the Company (approximately 45%).
Type restructuring
Charge $15 to $19 million
Affected area the Company
Headcount approximately 45%
Exact text from the filing
cash equivalents, restricted cash, and investments of $348.7 million as of September 30, 2024 • Anticipates a one-time restructuring charge in the fourth quarter of 2024 of $15 to $19 million and estimates post-restructuring annualized cash-based operating expense savings of more than $40 million • Reiterates 2024 net product revenue guidance range of
View on SEC.gov
Source: SEC EDGAR
accession 0001600620-24-000106
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.